NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Pathology Diagnostics Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New in Situ mRNA Detection Method Accurately Measures PD-L1 mRNA in Early Stage Breast Cancer - Solving the problem of PD-L1 measurement using antibody based techniques - PathologyDiagnostics.com
New in Situ mRNA Detection Method Accurately Measures PD-L1 mRNA in Early Stage Breast Cancer

 

NewswireToday - /newswire/ - Cambridge, Cambridgeshire, United Kingdom, 2014/07/25 - Solving the problem of PD-L1 measurement using antibody based techniques - PathologyDiagnostics.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new molecular analysis tool has been used to detect the level of an important target for immunotherapy in early-stage breast cancers, researchers at Yale University report in the journal Clinical Cancer Research (Clin Cancer Res; 20(10); 2773 82).

Blockade of the PD-1/PD-L1 pathway is an important axis for new oncology therapies against melanoma, breast, ovarian, colorectal and other cancers. Levels of tumour PD-L1 expression are indicative of tumour survival and response to treatment. Development of accurate reproducible PD-L1 test is imperative in the pharmaceutical and R&D healthcare setting. However measurement of PD-L1 protein levels is limited by lack of standardisation of tests and variable performance of antibodies.

The new diagnostic test, developed in the Rimm laboratory at Yale University Department of Pathology using RNAScope, measures the amount of PD-L1 mRNA in cancer tissues. It is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. In their published study analysing PD-L1 mRNA in 636 breast cancers, nearly 60% of tumours were positive for PD-L1 mRNA. Furthermore, PD-L1 mRNA levels are significantly associated with tumour infiltrating lymphocytes, breast cancer ER negative status and improved recurrence free survival.

These observations support the evaluation of PD-1/PD-L1 targeted therapies in breast cancer and offer new hope for the development of a robust clinical test for patient stratification.

Source: K. A. Schalper, V. Velcheti, D. Carvajal, H. Wimberly, J. Brown, L. Pusztai, D. L. Rimm. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas. Clinical Cancer Research, 2014; 20 (10): 2773 DOI: 10.1158/1078-0432.CCR-13-2702

Pathology Diagnostics Ltd (pathologydiagnostics.com) is an independent GCLP accredited histopathology research organisation delivering high-quality tissue laboratory & diagnostics services to industry Research & Development scientists engaged in drug and biomarker development.

Specialising in the provision of clinical diagnostics and quantitative image analysis on human tissues for studies ranging from early discovery to clinical trials, Pathology Diagnostics offers a range of services from traditional histopathology techniques to advanced digital pathology, whole slide scanning, central biorepository services and quantitative image analysis of biomarkers.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Pathology Diagnostics Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New in Situ mRNA Detection Method Accurately Measures PD-L1 mRNA in Early Stage Breast Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Marketing Officer - PathologyDiagnostics.com 
+44(0)12 2385 1354 as[.]pathologydiagnostics.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Pathology Diagnostics Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Pathology Diagnostics Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Limelon Advertising, Co.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)